Skip to main content
Jonathan E. Constance

Jonathan E. Constance, PhD

Languages spoken: English

Academic Information

Departments Primary - Pediatrics , Adjunct - , Adjunct -

Divisions:

Academic Office Information

Jonathan.Constance@hsc.utah.edu

Board Certification

  • American Board of Clinical Pharmacology

Jonathan Constance, Ph.D., is a Research Assistant Professor in the Division of Clinical Pharmacology.

Dr. Constance’s research seeks to better understand patient level factors, such as genetics, stage of development, pathophysiologic states, and polypharmacy that influence drug efficacy and risk in neonatal and pediatric populations. Of special interest are the pharmacokinetic and pharmacodynamic relationships between concomitant antineoplastic therapy and non-anticancer medications related to altered chemotherapeutic activity and efficacy among pediatric patients with cancer. This encompasses interests in the ontogeny of xenobiotic metabolizing enzymes and transporters, patterns of drug use, and targeted therapies such as tyrosine kinase inhibitors and peptide/protein drugs. Using clinical data, including genetic characteristics, to inform in vitro drug-drug interaction models with the aim of understanding the consequences of interpatient variability on drug efficacy and toxicity.

Teaching and training professional and graduate students in Pharmacology and Toxicology and Pediatric Clinical Pharmacology.

Education History

Fellowship University of Utah
Research Fellow
Postdoctoral Fellowship University of Utah
Clinical Fellow
Doctoral Training University of Utah
PhD
Undergraduate University of Utah
BS

Selected Publications

Journal Article

  1. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance JE (2020). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. J Adolesc Young Adult Oncol, 10(2), 175-184.
  2. Yellepeddi VK, Parashar K, Dean SM, Watt KM, Constance JE, Baker OJ (2020). Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. Clin Transl Sci, 14(2), 683-691.
  3. Biltaji E, Enioutina EY, Yellepeddi V, Rower JE, Sherwin CMT, Ward RM, Lemons RS, Constance JE (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leuk Lymphoma, 61(8), 1920-1931.